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Update on schizophrenia and bipolar disorder: 
focus on cariprazine
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Louisville, 2School of Nursing, 
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Abstract: Schizophrenia and bipolar disorder are severe psychiatric disorders that are frequently 
associated with persistent symptoms and significant dysfunction. While there are a multitude 
of psychopharmacologic agents are available for treatment of these illnesses, suboptimal 
response and significant adverse consequences limit their utility. Cariprazine is a new, novel 
antipsychotic medication with dopamine D2 and D3 partial agonist effects. Its safety and 
efficacy have been investigated in acute psychosis of schizophrenia, bipolar mania, bipolar 
depression, and unipolar depression. Efficacy has been demonstrated in schizophrenia and 
mania. It is unclear if cariprazine is effective in depression associated with unipolar or bipolar 
illness. Adverse consequences include extrapyramidal symptoms including akathisia, and 
various gastrointestinal symptoms. The US Food and Drug Administration (FDA) has recently 
approved cariprazine. This review will provide clinicians with basic information regarding the 
research program of cariprazine.
Keywords: cariprazine, dopamine D3 receptor, dopamine D2 receptor, bipolar disorder, mania, 
bipolar depression, schizophrenia
Introduction
Schizophrenia is a severe and persistent mental illness and treatment is woefully 
inadequate for the majority of afflicted individuals. Nearly all available antipsychotic 
agents are dopamine D2, D3, and/or D4 receptor antagonists.1 More recently, partial 
agonistic action at D2 and D3 receptors has suggested that this may be a promis-
ing approach.2 Three partial agonist compounds have now been approved for acute 
psychosis associated with schizophrenia by the US Food and Drug Administration 
(FDA): aripiprazole, brexpiprazole, and cariprazine. The newest of these, cariprazine, 
has unique properties that may affect its clinical profile.
Similarly, bipolar illness is a severe, recurring illness. While psychosis is a common 
symptom in manic and depressed individuals with bipolar I disorder, antipsychotic 
agents have demonstrated efficacy independent of the presence of psychosis.3 Further-
more, antipsychotics with antidepressant potential have helped fulfill an unmet need 
for bipolar patients.4,5 Cariprazine has been studied in this population as well.
Cariprazine is a piperazine derivative that was developed by Geoden-Richter in 
Hungary. Initially, scientists identified trans-N-[4-[2-[4-(2,3-dichlorophenyl)piperazin-
1-yl]ethyl]cyclohexyl]-N′,N′-dimethylurea hydrochloride or “2m” as an impurity in 
biosynthetic experiments.6 However, subsequent analysis revealed that this impurity 
was more promising than the original research target.6 The drug was subsequently 
named cariprazine (RGH-188) and investigated clinically for both schizophrenia and 
depression in unipolar and bipolar illness.
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Pharmacodynamics and 
pharmacokinetics
Cariprazine is a partial agonist at the dopamine D2 and D3, 
and the serotonin 5HT
1A
 receptors.7 It has high affinity to 
these receptors (Ki =0.5, 0.085, and 3.0 nM, respectively8) 
as well as serotonin 5HT
2B
 and 5HT
2A
 receptors.8 At doses 
approaching 2–3 mg per day, cariprazine receptor occupancy 
easily exceeds 85% for D2 and D3 receptors in monkeys.9 
In humans with schizophrenia, 1.5 mg daily will achieve 
69%–75% receptor occupancy.10 In nonpsychotic controls, 
doses of 1 mg daily achieve over 65% receptor occupancy.11 
Serotonin 5HT
1A
 receptor occupancy never exceeds 30% 
despite a high affinity.9 Cariprazine is safe and effective in 
dose ranges 3–12 mg daily.
The half-life of cariprazine is ~2–6 days.12,13 C
max
 for 
cariprazine is achieved in 3–4 hours after an oral dose, but 
because of a half-life of 2–6 days, achieves steady state in 
over a week.12,13 Furthermore, it has two active metabolites, 
desmethyl-cariprazine and didesmethyl-cariprazine,14 which 
prolong time to functional steady state to over 1 month. 
Metabolism occurs through CYP450 3A4 and, to a lesser 
extent, CYP450 2D6.15
Partial dopamine agonist antipsychotics allow clinicians 
to obtain clinical efficacy while minimizing dopamine-related 
adverse events (AEs). Dopamine-mediated AEs occur 
when receptor occupancy exceeds 80%16 in both animals17 
and humans.18,19 This is so close to the 65% D2 occupancy 
which is required to achieve the antipsychotic effect20,21 that 
it is difficult to titrate the dose appropriately, and clinicians 
generally use antipsychotics at 90% occupancy.22
Cariprazine, and other high-affinity partial agonists, solve 
this problem. When cariprazine is administered at a dose 
that occupies 95% of the D2 receptors, the partial activation 
produces an apparent lower level of blockade. The level of 
partial activation needs to mimic the natural tonic dopamine 
signal in the brain, ~20%–25% of the maximal dopamine 
signal.23 Thus, partial agonists must stimulate the D2 receptor 
at a level similar to this. Cariprazine may reduce the risk of 
dopamine-related AEs even further due to its partial agonistic 
effect on 5HT
1A
, which may reduce extrapyramidal symp-
toms and improve mood and cognition.24–26 The reduction 
of D2-mediated AEs is essentially quantified in the serum 
prolactin data. In long-term safety studies in patients with 
schizophrenia, mean prolactin levels drop by 18.3 ng/mL at 
48 weeks versus baseline (dose range from 1.9 to 9 mg/day). 
While some of this reduction may be related to some of the 
patients coming off a prolactin-increasing antipsychotic, the 
reduction is consistent with the activation of D2 receptors 
at/near the natural tonic level of dopamine by the partial 
agonist effect of the drug.
Partial agonism may also play an important role that is 
specific to the pathophysiology of schizophrenia. Recent 
positron emission tomography studies suggest that patients 
with early or chronic schizophrenia have an increase in 
dopamine synthesis and dopamine release.27–30 However, 
the synaptic density is unchanged versus controls,31 sug-
gesting that the amount of dopamine per synapse in 
patients with schizophrenia is increased. Indeed, there is 
evidence that in subjects with schizophrenia and at-risk 
individuals, the dopamine system is hyperresponsive.30,32 
A high-affinity partial agonist will fully prevent endogenous 
dopamine from interacting with postsynaptic receptors while 
creating a partial dopamine signal that normalizes functional 
dopamine signal.
Cariprazine is generally described as a D3-preferring 
agent. The D3 receptor has the highest density of expression 
in the nucleus accumbens and olfactory tubercle.27–29 Over-
expression of D3 reduces motivation in mice,30 and blockade 
of D3 improves cognition and reduces hyperactivity in rats.31 
While antipsychotics frequently block D3,32,33 and a genetic 
variant of this receptor has been associated with risk of devel-
oping tardive dyskinesia,34 cariprazine is a partial agonist, 
so that some stimulation of the receptor continues even at 
maximal receptor occupancy. As would be expected from 
the receptor profile, cariprazine has demonstrated efficacy 
in animal models that examine cognition,24,35 depression,25 
and mania.36
Cariprazine in schizophrenia
Four acute studies performed in subjects with schizophrenia 
have either been published directly,37 or presented in meetings 
and published in review format.38,39 In an early Phase II study, 
392 subjects with acute schizophrenic psychosis were random-
ized to receive 1.5–3 mg/day or 3–6 mg/day of cariprazine or 
placebo, after a 7-day washout, and followed for 6 weeks.38,39 
A large fraction (46%) discontinued the study early for a vari-
ety of reasons. A larger fraction of patients receiving placebo 
(15%) stopped the study for lack of efficacy than in either 
active arm (8% in the low-dose arm and 9% in the high-dose 
arm).38 The score of the Positive and Negative Syndrome 
Scale (PANSS) improved significantly in patients receiving 
1.5–3 mg/day of cariprazine compared to placebo; the higher 
dose arm did not statistically separate from placebo.38
A second Phase II study which has been published40 
randomized 732 subjects with acute schizophrenic psychosis 
to one of five arms: cariprazine 1.5 mg/day, 3 mg/day, 
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4.5 mg/day, placebo, or risperidone 4 mg/day for 6 weeks. 
All active arms improved significantly compared to placebo. 
There appeared to be a dose-related change in magnitude 
of PANSS change with a least squares mean difference 
(LSMD) of -7.6, -8.8, and -10.4 for 1.5, 3, and 4.5 mg/day 
of cariprazine, respectively; risperidone change was -15.1, 
but the study was not powered to examine differences in the 
active arms.40
A Phase III study randomized 617 patients to cariprazine 
3 mg/day or 6 mg/day, aripiprazole 10 mg/day, or placebo. 
All active arms improved significantly compared to placebo. 
The cariprazine 6 mg/day arm and aripiprazole group 
separated from placebo at week 1; the low-dose cariprazine 
arm separated from placebo at week 3 (due to the long half-
life and delay in reaching steady state).38
A second Phase III study randomized 446 people with 
acute schizophrenia to three arms: cariprazine 3–6 mg/day 
(n=151), cariprazine 6–9 mg/day (n=1,480), and placebo 
(n=147).37 Both active arms improved significantly relative 
to placebo, but again there appeared to be a numerical dose 
effect with LSMD of -6.8 for the low-dose arm and -9.9 for 
the high-dose arm.37
Across the three published schizophrenia studies, males 
outnumbered females by a ratio of approximately 3:1.37,38,40 
There were no reported differences in efficacy or AEs 
between the sexes.
In summary, short-term studies performed with cari-
prazine in patients with acute exacerbation of schizophrenia 
revealed the drug to be effective in a wide range of doses, 
and revealed that the extent of improvement is similar to 
established second-generation antipsychotics. There may 
be evidence of dose-responsiveness in the antipsychotic 
effect. This may be a true pharmacodynamics effect, or may 
be related to a pharmacokinetic effect where lower doses 
require a longer time to reach levels achieved at higher 
doses, and steady-state levels are not achieved in the brief 
6-week period.
The side-effect profile in both the short-term and long-
term studies was similar for patients with bipolar illness and 
patients with schizophrenia. The safety profile of cariprazine 
is discussed in the following section.
Efficacy in bipolar illness
Three randomized controlled trials have been conducted in 
patients with mania.38,41 A Phase II study randomized 238 
adults to either a flexible-dose cariprazine (3–12 mg/day) 
or placebo.41 The majority of patients (66.1%) reached 
12 mg/day, and the average dose was 8.8 mg/day.41 
The LSMD by week 3 was -6.12 points on the Young Mania 
Rating Scale (YMRS) (Figure 1). Approximately, half of 
the patients (48%) achieved at least a 50% improvement, or 
became euthymic (42%) compared to one-quarter of placebo-
treated patients (25% and 23%, respectively).37,41 As with 
nearly all of the cariprazine studies, dropout rates were high, 
so that 61.9% (n=73) of the placebo group and 63.6% (n=75) 
of the cariprazine group completed the study.37,41
Two Phase III trials with manic patients have been 
presented. The first trial randomized 312 acutely manic 
adults to either a flexible-dose cariprazine or placebo. 
Over half of the patients responded (59%) or achieved 
remission (52%) on cariprazine compared to significantly 
smaller numbers on placebo (44% and 35%, respectively).42 
The LSMD in YMRS score was -4.3 for the cariprazine-
treated patients.42
In the second Phase III trial, 497 manic patients with 
mania were randomized to cariprazine 3–6 mg/day, 
6–12 mg/day, or placebo.43 The YMRS LSMD was essen-
tially the same for both dose ranges (-6.1 points for the lower 
dose and -5.9 points for the higher dose, both P,0.001).43 
Only 25% of patients in this study achieved remission.
Cariprazine was also investigated as a potential anti-
depressant in depressed patients with bipolar and unipolar 
disorders. In a Phase II study, 233 depressed subjects with 
bipolar disorder were randomized to a very-low-dose arm 
(0.25–0.75 mg/day), a low-dose arm (1.5–3.0 mg/day), and 
placebo. There was no statistically significant separation from 
placebo.44 In a subsequent study, 584 depressed patients with 
bipolar disorder were treated for 8 weeks with cariprazine 
0.75 mg/day, 1.5 mg/day, 3.0 mg/day, or placebo.45 The group 
receiving 1.5 mg of cariprazine improved transiently at week 6 
(four-point improvement on Montgomery–Åsberg Depres-
sion Rating Scale, P=0.003).45 These findings mirror other 
Figure 1 The reduction in the Young Mania Rating Scale (YMRS) for manic subjects 
being treated with cariprazine and placebo over 21 days (last observation carried 
forward).
Note: Data from Kane et al.37
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observations with partial agonists. Brexpiprazole, which is 
a partial agonist antipsychotic drug recently approved as an 
adjunct for the treatment of unipolar depression, appeared to 
have a therapeutic window – in which 2 mg/day was more 
effective than both 1 mg and 3 mg daily.46,47 Thus, the observa-
tion that 1.5 mg/day of cariprazine is more effective than either 
a lower dose or a higher dose is not without precedent in this 
class of medications. Similarly, the phenomenon of a transient 
improvement was also observed with aripiprazole in bipolar 
depression48 and may be a reflection of the combination of 
a therapeutic window and long drug half-life. Repeating the 
study with 1 mg/day for a longer time period may clarify the 
actual efficacy of cariprazine in bipolar depression.
However, these conjectures are not supported by a Phase II 
study where the condition of 231 patients with treatment-
resistant unipolar depression receiving 0.1–0.3 mg/day or 
1.0–2.0 mg/day added to an antidepressant did not improve.49 
Furthermore, the condition of 819 patients who received 
a higher dose of cariprazine added to an antidepressant 
for 8 weeks (2.0–4.5 mg/day + antidepressant) improved 
compared to placebo + antidepressant (P=0.0114).50 Thus, 
cariprazine may indeed have efficacy in the treatment of 
depression (unipolar and/or bipolar), but the full nature of 
that effect is not clear.
Safety and tolerability
Cariprazine has been approved for use in patients with 
acute exacerbation of schizophrenia and bipolar mania 
(including mixed states). The AE profile in the short-term 
studies in schizophrenia and bipolar disorders is very 
similar.38–41,51–54
While the efficacy of cariprazine appears to be dose-
related, so that doses of 3.0–4.5 mg once daily are generally 
more effective than lower doses, tolerability does not appear to 
be dose-related.40 In most acute studies, more placebo-treated 
subjects compared to cariprazine discontinued treatment due 
to insufficient therapeutic response.40 Compared to other 
FDA-approved second-generation atypical antipsychotics, 
cariprazine is less likely to produce clinically significant 
metabolic side effects, such as weight gain, hyperlipidemia, 
hypercholesterolemia, and hyperglycemia, with any 
observed changes being similar to placebo.37,40,55 There are 
no significant ECG abnormalities55 and prolactin levels 
usually drop.55 Common AEs are either central (in order of 
decreasing frequency: insomnia, extrapyramidal symptoms, 
akathisia, sedation, dizziness, and anxiety) or gastrointestinal 
(nausea, constipation, and vomiting).7,40,41 In patients with 
bipolar illness, measuring akathisia (utilizing the Barnes 
Akathisia Rating Scale) reveals a nonsignificant increase 
in akathisia with cariprazine versus placebo (0.4 vs 0.09, 
P=0.12).41 However, when parkinsonism is measured by the 
Simpson Angus Scale, there is a significantly greater level of 
extrapyramidal symptoms in patients receiving cariprazine 
(1.17) versus placebo (0.09, P,0.01).41 In most studies, 
AEs did not appear to be dose related.41,55 However, in one 
unpublished acute mania study, AEs occurred at greater 
frequency at higher doses (6–12 mg/day) compared to lower 
doses (3–6 mg/day), and both greater than placebo.7
There were no reported abnormalities in liver function 
or P450 enzyme function with cariprazine treatment. How-
ever, due to the long half-life of the drug and its equipotent 
active metabolites, the FDA added a warning that caripra-
zine may have late-occurring AEs, occurring after weeks 
of treatment.
In summation, cariprazine was considered safe and well 
tolerated among adult patients diagnosed with acute schizo-
phrenia and bipolar mania.
Conclusion
Partial agonists of the dopamine system are becoming the 
preferred class of medications over pure antagonists in 
treatment of both psychosis and mood disturbance. This is 
because tolerance to the medication is less likely to occur 
when the receptor is both blocked and stimulated at the same 
time. Cariprazine is a partial agonist at D2, D3, and 5HT
1A
 
receptors. The affinity at the D3 receptor is approximately 
six times greater than at the D2 receptor. However, it is 
administered at a dose that generally blocks the majority of 
both of these receptors.
Studies with partial agonists, particularly with long half-
lives are frequently difficult to predict, and this appears to be 
the case with cariprazine. In studies with patients with bipolar 
mania or schizophrenic psychosis, cariprazine has shown 
significant efficacy and a tolerable AE profile. However, it is 
much more difficult to interpret the depression data. The data 
are consistent with the interpretation of a window in which the 
drug may be effective with depression, in a manner similar 
to aripiprazole and brexpiprazole. The task of understanding 
the effect of the drug is made more difficult by the paucity of 
publications of the completed clinical trials. Nonetheless, the 
recent approval of cariprazine provides a new tool for clini-
cians, which appears to have unique mechanistic profile.
Disclosure
Dr Rif S El-Mallakh has grant funding from the National 
Institute of Mental Health, the State of Kentucky, Merck, 
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